Financial Statements

Myriad Genetics, Inc. (MYGN)

$16.27

+0.28 (+1.75%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands , Years are calendar years not fiscal years

Retained Earning Schedule

Year 2022 2021 2020 2019 2018
Retained Earnings (Previous Year) -254-1742653-
Net Income -112-27-2005131
Stock Dividends --53-308-78
Dividend Paid ----340-
Retained Earnings -366-254-1742653

PPE Schedule

Year 2022 2021 2020 2019 2018
Gross PPE 1251035743-
Annual Depreciation 10740562352
Capital Expenditure -45-18-10-9-8
Net PPE 1871251035743

Intangible and Goodwill Schedule

Year 2022 2021 2020 2019 2018
Intangible and Goodwill (Previous Year) -319417328239
New Purchases -81-79-61-148-103
Intangible and Goodwill 319417328239287

Myriad Genetics, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Myriad Genetics, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.